A Phase 4 interventional study of follitropin beta and ganirelix acetate in Infertility, sponsored by University of Pennsylvania. Completed at 1 site in United States. Open to female participants aged 20 Years to 42 Years. Per ClinicalTrials.gov, last updated 2015-12-03.
Sponsored by University of Pennsylvania · Phase 4, Interventional, and Treatment
In vitro fertilization (IVF) is a common procedure used to assist couples who have difficulty conceiving a pregnancy. IVF is a process where oocytes (eggs) are retrieved from a woman's ovaries and fertilized with sperm in the laboratory. In order to maximize the number of oocytes that can be retrieved, a women undergoes ovarian stimulation with recombinant follicle stimulating hormone (FSH). Typically 6-20 oocytes are retrieved, but in some cases there is a limited response to the stimulation, producing a limited number of oocytes. This is called poor ovarian response.
This study is designed to objectively compare two treatment regimens currently advocated in clinical practice, but never compared directly. The purpose is to assess ovarian response to starting treatment at the end of the preceding cycle may increase the number of developing oocytes.
2,540 studies on the registry are indexed under Infertility; 405 are open to participants now.
This study's enrollment of 20 is below the median of 120 across 1,722 interventional studies indexed under Infertility.
Browse Infertility studies →University of Pennsylvania is the lead sponsor of 1,664 studies on the registry; 236 are open to participants now.
Of its 156 completed or terminated interventional studies of FDA-regulated products, 107 (69%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Poor ovarian response in most-recent previous IVF cycle within the past 18 months as defined by the following criteria:
A) \<5 dominant follicles day of hCG, B) \<5 oocytes retrieved, or C) cancellation of a previous IVF cycle due to poor response to ovulation stimulation.
Exclusion Criteria:
Follitropin beta
Drug: follitropin beta
Ganirelix acetate
Drug: ganirelix acetate
Follitropin beta
Ganirelix acetate
Number of oocytes retrieved for IVF
Time frame: One cycle
Number of follicles >10mm on day of human chorionic gonadotropin (hCG) administration;
Time frame: 1 cycle
Number of days of stimulation;
Time frame: 1 cycle
Estradiol level on the day of hCG administration;
Time frame: 1 cycle
Clinical pregnancy rate per transfer: defined as the presence of an intrauterine sac on transvaginal ultrasound;
Time frame: 1 cycle
Delivery rate per transfer;
Time frame: 1 cycle
Safety (incidence of ovarian torsion, severe risk of ovarian hyperstimulation syndrome, enlarging hemorrhagic cysts, and serious adverse events)
Time frame: 1 cycle
This study is completed, as verified in Dec 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Follitropin beta · Ganirelix